Loading
CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.
Latest quote
¥770
−¥23.00 · -2.90%
Regular session · JST · Market data may be delayed.
CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.
Day range
Current ¥770
52-week range
Current ¥770
Regular session · JST · Market data may be delayed.
CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.
Day range
Current ¥770
52-week range
Current ¥770
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 820M JPY | 984M JPY | 671M JPY | 608M JPY |
| Gross profit | — | −820M JPY | −984M JPY | −671M JPY | −608M JPY |
| Research and development | 1.06B JPY | 820M JPY | 983M JPY | 671.04M JPY | 607.78M JPY |
| Selling, general, and administrative | 301.17M JPY | 289M JPY | 191M JPY | 294.92M JPY | 175M JPY |
| Operating expenses | 1.36B JPY | 1.11B JPY | 278M JPY | 965.96M JPY | 846.44M JPY |
| Interest income | 4.46M JPY | 1.41M JPY | 32K JPY | 21K JPY | 17K JPY |
| Interest expense | — | — | — | 1.17M JPY | 5.68M JPY |
| Depreciation and amortization | — | 1.11B JPY | 1.26B JPY | — | — |
| Operating income | −1.36B JPY | −1.11B JPY | −1.26B JPY | −965.97M JPY | −846.44M JPY |
| Net income | −1.31B JPY | −1.16B JPY | −1.21B JPY | −1.24B JPY | −855.58M JPY |
Company facts updated Sep 7, 2026.
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
